Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015–2020

References

• NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Version 9.2 [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. 2022 [cited 2003 May 15]. Available from: https://nordcan.iarc.fr/
   Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2023;41(23):3881–3890. doi:10.1200/JCO.2000.18.17.3068.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50–54. doi:10.1016/j.ejca.2005.08.032.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Alimohamed N, Grewal S, Wirtz HS, et al. Understanding treatment patterns and outcomes among patients with de novo unresectable locally advanced or metastatic urothelial cancer: a population-level retrospective analysis from Alberta, Canada. Curr Oncol. 2022;29(10):7587–7597. doi:10.3390/curroncol29100599.
   PubMed Web of Science ®Google Scholar
• Kita Y, Ito K, Sano T, et al. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era. Int J Urol. 2022;29(7):647–655. doi:10.1111/iju.14861.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S179083.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3.
   PubMed Web of Science ®Google Scholar
• Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;39(7 Suppl):72–74. doi:10.1177/1403494810393563.
   PubMedGoogle Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56. doi:10.2147/clep.s9908.
   PubMedGoogle Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S91125.
   PubMed Web of Science ®Google Scholar
• Sørup S, Darvalics B, Knudsen JS, et al. Identifying valid algorithms for number of lines of anti-neoplastic therapy in the Danish National Patient Registry among patients with advanced ovarian, gastric, renal cell, urothelial, and non-small cell lung cancer attending a Danish University Hospital. Clin Epidemiol. 2022;14:159–171. doi:10.2147/CLEP.S342238.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798–798f. doi:10.1093/ije/dyw213.
   PubMed Web of Science ®Google Scholar
• Sundhedsdatastyrelsen. DRG-takster. 2023 [cited 2023 June 27]. Available from: https://sundhedsdatastyrelsen.dk/da/afregning-og-finansiering/takster-drg.
   Google Scholar
• Wilke T, Zhang L, Hubscher E, et al. 1765P undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la/mUC): a systematic literature review. Ann Oncol. 2022;33:S1345. doi:10.1016/j.annonc.2022.07.1843.
   Web of Science ®Google Scholar
• Omland LH, Joensen UN, Toft BG, et al. Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma. Acta Oncol. 2022;61(9):1036–1042. doi:10.1080/0284186X.2022.2114378.
   PubMed Web of Science ®Google Scholar
• Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Eur Urol. 2021;80(1):7–11. doi:10.1016/S0140-6736(17)33297-X.
   PubMed Web of Science ®Google Scholar
• Feng Y-N, Xie G-Y, Xiao L. Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN bladder 100 phase 3 trial. Eur Urol. 2023;S0302-2838(23):03072-5. doi:10.1016/j.eururo.2023.07.021.
   Google Scholar
• Puente J, Pinto A, Vidal MJM, et al. Real-world treatment patterns, survival outcomes, and health care resource utilization (HCRU) for locally advanced or metastatic urothelial carcinoma (la/mUC) in Spain. J Clin Oncol. 2023;41(6_suppl):463–463. doi:10.1200/JCO.2023.41.6_suppl.463.
   Google Scholar
• Hansen E, Larsson H, Norgaard M, et al. The Danish bladder cancer database. Clin Epidemiol. 2016;8:439–443. doi:10.2147/CLEP.S99491.
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Broughton E, Hao Y, et al. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol. 2022;40(5):195.e1–195.e11. doi:10.1016/j.urolonc.2021.11.014.
   PubMed Web of Science ®Google Scholar